Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150

By sjmartinez • December 18, 2024

Finn RS, Galle PR, Ducreux M, Cheng AL, Reilly N, Nicholas A, Hernandez S, Ma N, Merle P, Salem R, Li D, Breder V. Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150. Liver Cancer. 2024 Jun 21;13(6):655-668. doi: 10.1159/000539897. PMID: 39687036; PMCID: PMC11649257.

Tags: Hematology/Oncology, High-risk prognostic factors, immunotherapy, PD-L1 inhibitor, Portal vein tumor thrombosis, Publications, Vp4

PKC inhibitors reveal PKC isoforms involved in HIV latency reversal and immunomodulation

Zaikos TD, Pham V, Chou TC, Moran JA, Turner SR, Yu BH, Hourani R, Ranjan A, Zack JA, Wender PA, Marsden MD. PKC inhibitors reveal[...]

Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy

Carlson SG, Puliafito BR, Kawai K, Senaratne TN, Lee TD, Lin T, Timmerman J, Larson SM. Impact of clonal hematopoiesis of indeterminate potential on treatment[...]

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

Owen RG, McCarthy H, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Cheson[...]